Last reviewed · How we verify
Placebo to match FF/UMEC/VI
Placebo to match FF/UMEC/VI is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Clinical trial control comparator (not a therapeutic agent).
This is an inert placebo formulation designed to match the physical and sensory characteristics of the active FF/UMEC/VI combination inhaler.
This is an inert placebo formulation designed to match the physical and sensory characteristics of the active FF/UMEC/VI combination inhaler. Used for Clinical trial control comparator (not a therapeutic agent).
At a glance
| Generic name | Placebo to match FF/UMEC/VI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Placebo products contain no pharmacologically active ingredients and serve as control comparators in clinical trials. This specific placebo is manufactured to match the appearance, taste, feel, and delivery mechanism of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) to maintain blinding in randomized controlled trials.
Approved indications
- Clinical trial control comparator (not a therapeutic agent)
Common side effects
Key clinical trials
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2 (PHASE3)
- A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match FF/UMEC/VI CI brief — competitive landscape report
- Placebo to match FF/UMEC/VI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo to match FF/UMEC/VI
What is Placebo to match FF/UMEC/VI?
How does Placebo to match FF/UMEC/VI work?
What is Placebo to match FF/UMEC/VI used for?
Who makes Placebo to match FF/UMEC/VI?
What development phase is Placebo to match FF/UMEC/VI in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Clinical trial control comparator (not a therapeutic agent)
- Compare: Placebo to match FF/UMEC/VI vs similar drugs
- Pricing: Placebo to match FF/UMEC/VI cost, discount & access